Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKIPPirr: Prevention of Infusion Related Reactions with Amivantamab in EGFRm NSCLC
NCT05663866Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 2, open-label trial of dexamethasone, montelukast and methotrexate in infusion-related reaction (IRR), sponsored by Janssen Pharmaceutical. Primary endpoint: Infusion-related Reactions. Started May 2023; status: active, not recruiting.
02
Drugs
dexamethasonemontelukastmethotrexate
03
Conditions
infusion-related reaction (IRR)
Beyond the preview
Go deeper on NCT05663866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663866.